GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 283.00
Bid: 281.00
Ask: 283.00
Change: -7.00 (-2.41%)
Spread: 2.00 (0.712%)
Open: 285.00
High: 285.00
Low: 283.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TOP NEWS: Retailer ASOS now to be seen on London Main Market

Thu, 13th Jan 2022 09:10

(Alliance News) - Online fashion retailer ASOS on Thursday revealed plans to move to the London Main Market, saying it has outgrown AIM after 20 years, most of that time as its biggest listing.

ASOS, which stands for "as seen on screen", long dominated the junior market, though its current market capitalisation of GBP2.42 billion places it fifth in size on AIM. Currently the largest stock traded on AIM is Hutchmed (China) Ltd with a GBP4.18 billion market cap, followed by Abcam PLC and Fevertree Drinks PLC. The move would also put ASOS in contention to join the FTSE 250 index.

ASOS shares were up 8.2% at 2,443.00 pence in London on Thursday morning.

"ASOS directors believe that given ASOS's size and scale, now is the appropriate time to move from AIM to a premium Main Market listing," the company said, explaining it thinks the move will raise its corporate profile and recognition, and increase investment in its shares by global institutions.

ASOS said it will move its listing by the end of February. JP Morgan will act as sponsor for the Main Market admission, which won't involve any fund raise.

In conjunction with the shift, ASOS has hired Patrick Kennedy as senior independent director. Kennedy, the former chief executive of Irish betting firm Paddy Power - now Flutter Entertainment PLC - is the chair of Bank of Ireland Group PLC. He holds 23,000 ASOS shares, which are worth about GBP560,000.

ASOS also provided a trading update for the last four months of 2021.

Total revenue rose by 2.1% to GBP1.39 billion from GBP1.36 billion a year before. In constant currency, the increase was 5%. UK sales rose by 13%, while EU sales rose by 2% and US sales by 11%, both at constant currency. However, Rest of World sales fell by 15% at constant currency and by 20% at actual rates.

ASOS said that while UK sales benefited from Britons going out once again, the fourth wave of Covid-19 limited this in Europe. In the US, ASOS note significant port congestion and supply chain disruption, restricting its ability to fulfil orders. ROW sales also were hurt by "the continued impact of extended delivery propositions".

Gross margin narrowed by 400 basis points to 43.0%, as expected, ASOS said, due to clearance activity. The product returns rate has normalised in line with expectations.

ASOS said that, despite uncertainty related to the Omicron variant of Covid-19, its full-year guidance remains unchanged at 10% to 15% revenue growth and adjusted pretax profit of GBP110 million to GBP140 million. In the financial year that ended August 31, 2021, ASOS recorded GBP3.91 billion in revenue, up from GBP3.26 billion the year before, with adjusted pretax profit of GBP193.6 million, up from GBP142.1 million.

"Our listing on AIM for the past 20 years has been an important part of ASOS's development, but the time is now right to move to the Main Market as we focus on delivering our medium-term guidance and longer-term growth ambitions," said Chief Operating Officer Mat Dunn.

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
7 Feb 2024 09:50

Hutchmed hails fruquintinib trial results for gastric cancer treatment

(Alliance News) - Hutchmed (China) Ltd on Wednesday said phase three data for fruquintinib in combination with paclitaxel showed an improvement in overall survival for patients with gastric or gastroesophageal junction adenocarcinoma.

Read more
2 Feb 2024 09:52

Hutchmed says Inmagene exercises option to licence drug candidates

(Alliance News) - Hutchmed (China) Ltd on Friday said Inmagene Biopharmaceuticals Ltd has exercised options to licence two drug candidates as part of a strategic partnership.

Read more
2 Feb 2024 09:42

Hutchmed partner Inmagene exercises options over two drug candidates

(Sharecast News) - Hutchmed China announced on Friday that Inmagene Biopharmaceuticals has exercised options to licence two drug candidates, IMG-007 and IMG-004, as part of their strategic partnership.

Read more
30 Jan 2024 10:32

Hutchmed's 'Elunate' approved under new Hong Kong rules

(Sharecast News) - Hutchmed China announced the approval of its drug 'Elunate', or fruquintinib, by the Pharmacy and Poisons Board of Hong Kong on Tuesday, for the treatment of adult patients with previously treated metastatic colorectal cancer (CRC).

Read more
30 Jan 2024 09:20

Hutchmed celebrates cancer drug approval in hometown of Hong Kong

(Alliance News) - Hutchmed (China) Ltd on Tuesday touted progress in Hong Kong, after its oral therapy for metastatic colorectal cancer received marketing approval in the city.

Read more
11 Jan 2024 11:11

Hutchmed application for thrombocytopenia treatment accepted in China

(Sharecast News) - Hutchmed China announced on Thursday that the new drug application (NDA) for sovleplenib, an oral inhibitor targeting spleen tyrosine kinase (Syk), had been accepted for review and granted priority review by China's National Medical Products Administration (NMPA).

Read more
11 Jan 2024 10:17

TOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureau

(Alliance News) - Hutchmed Ltd on Thursday said that its novel treatment for haematological malignancies and immune diseases had been progressed to the next stage of approval by the country's national bureau for drug supervision.

Read more
21 Dec 2023 11:36

IN BRIEF: Hutchmed China renews deals with "substantial" shareholders

Hutchmed (China) Ltd - Hong Kong-based developer of treatments for cancer and immunological diseases - Agrees with "substantial shareholder" Sinopharm Group Co Ltd to renew the Framework Sinopharm Products Supply & Purchase Agreement, effective from January 1, for three years up to and including December 31, 2026. Also agrees with HCMH to renew the HBYS Brand License Royalty agreement, also effective from January 1 and for the same duration. HCMH entered the HBYS deal in June 2021 with HWEL, a subsidiary of major shareholder CK Hutchison Holdings Ltd which holds an approximate 38.18% stake in Hutchmed.

Read more
13 Dec 2023 13:56

Hutchmed completes enrolment for fruquintinib trial

(Alliance News) - Hutchmed (China) Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
13 Dec 2023 12:20

Hutchmed completes trial enrolment, keeps drugs on China funding list

(Sharecast News) - Hutchmed China announced a significant milestone in its clinical trials on Wednesday, as well as the inclusion of two of its drugs on the National Reimbursement Drug List (NRDL) in China.

Read more
9 Nov 2023 12:16

Hutchmed hails Takeda's fruquintinib approval from US for cancer form

(Alliance News) - Hutchmed (China) Ltd on Thursday announced that the Tokyo-based drug maker, Takeda Pharmaceutical Co Ltd, has received US approval of fruquintinib for a form of colorectal cancer.

Read more
29 Sep 2023 10:57

Hutchmed confirms new drug application for fruquintinib in Japan

(Sharecast News) - Hutchmed China announced on Friday that its partner Takeda has officially submitted a new drug application (NDA) for fruquintinib to the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Read more
29 Sep 2023 10:12

Hutchmed notes Takeda submits fruquintinib drug application in Japan

(Alliance News) - Hutchmed (China) Ltd on Friday said Takeda Pharmaceutical Co Ltd has submitted a new drug application for cancer treatment fruquintinib to the Ministry of Health, Labour & Welfare in Japan.

Read more
14 Sep 2023 13:09

Director dealings: IPF non-exec picks up shares, Hutchmed China director linked to sale

(Sharecast News) - International Personal Finance was among the companies on the list of director purchases on Thursday after a non-executive director spent more than £18k on shares.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.